Cargando…
Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy
Background: Although catalytic properties of different genetic polymorphisms of VKORC1 and CYP2C9 products have been identified, there is limited study available regarding warfarin dose requirement in Iranian patient population. This study investigates the impact of these polymorphisms on 115 patien...
Autores principales: | Poopak, Behzad, Rabieipoor, Saghar, Safari, Nazila, Naraghi, Emadedin, Sheikhsofla, Fatemeh, Khosravipoor, Gelareh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748690/ https://www.ncbi.nlm.nih.gov/pubmed/26865929 |
Ejemplares similares
-
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance
por: Rejali, Leili, et al.
Publicado: (2015) -
Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
por: Jia, LiQun, et al.
Publicado: (2017) -
Association of Warfarin Therapy with APOE and VKORC1 Genes Polymorphism in Iranian Population
por: Rafiee, Sajad, et al.
Publicado: (2017) -
Effects of CYP2C9 and VKORC1 polymorphisms on warfarin sensitivity and responsiveness during the stabilization phase of therapy
por: AL-Eitan, Laith N., et al.
Publicado: (2019) -
The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
por: Taşkın, Birce Dilge, et al.
Publicado: (2016)